MannKind Corp

Update in progress

MNKD (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

MannKind Corporation is a biopharmaceutical company focused on novel solutions for chronic disease care. It develops and markets therapies for diabetes, pulmonary hypertension, heart failure, and chronic kidney disease. Products include Afrezza inhaled insulin, the V-Go wearable insulin delivery device, Tyvaso DPI, and FUROSCIX for fluid buildup. It also works on MNKD-201 and MNKD-701 for lung diseases, with collaborations with United Therapeutics and Thirona. Based in Danbury, CT, founded in 1991.

Company score

Sentiment: 0.30; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive